ReviewFrontiers in pharmacology2017
The Anti-allergic Cromones: Past, Present, and Future.
Review in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Small-Molecule NANT Therapeutics Targeting the Brain-Immune Axis in Alzheimer's Disease: Mechanisms, Clinical Progress, and Translational Challenges.Molecules (Basel, Switzerland) · 2026Review
- Diamine Oxidase and Gastrointestinal Diseases.Biomolecules · 2026Review
- Mast cell proteases and their significance in physiology, pathology, and therapeutic approaches.Pharmacological reviews · 2026Review
- Functional MRGPRX2 expression on peripheral blood-derived human mast cells increases at low seeding density and is suppressed by interleukin-9 and fetal bovine serum.Frontiers in immunology · 2024Article
- Mast cell stabilizers: from pathogenic roles to targeting therapies.Frontiers in immunology · 2024Review
- Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19.Biomedicines · 2022Review
- COVID-19 and the role of cytokines in this disease.Inflammopharmacology · 2022Review
- From NSAIDs to Glucocorticoids and Beyond.Cells · 2021Review
- Food Intolerance: The Role of Histamine.Nutrients · 2021Review
- Review
- Cromolyn inhibits the secretion of inflammatory cytokines by human microglia (HMC3).Scientific reports · 2021Article
- A Phosphatase-Mimetic Nano-Stabilizer of Mast Cells for Long-Term Prevention of Allergic Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Novel Strategies to Target Mast Cells in Disease.Journal of innate immunity · 2021Review
- RETRACTED: Genetic Deficiency and Pharmacological Stabilization of Mast Cells Ameliorate Pressure Overload-Induced Maladaptive Right Ventricular Remodeling in Mice.International journal of molecular sciences · 2020Article
- Design of Potential Pharmaceutical-Based Metal Complexes Derived from Cromolyn a Mast Cell Stabilizer.ACS omega · 2020Article
- Tackling the cytokine storm in COVID-19, challenges and hopes.Life sciences · 2020Review
- Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer.European clinical respiratory journal · 2020Article
- Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19.Frontiers in pharmacology · 2020Article
- Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The anti-allergic cromones were originally synthesized in the 1960s by Fisons Plc, and the first drug to emerge from this program, disodium cromoglycate was subsequently marketed for the treatment of asthma and other allergic conditions. Whilst early studies demonstrated that the ability of the cromones to prevent allergic reactions was due to their 'mast cell stabilizing' properties, the exact pharmacological mechanism by which this occurred, remained a mystery. Here, we briefly review the history of these drugs, recount some aspects of their pharmacology, and discuss two new explanations for their unique actions. We further suggest how these findings could be used to predict further uses for the cromones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.